HomeRecent ArticlesKaneka Acquires EndoStream Medical Ltd.

Kaneka Acquires EndoStream Medical Ltd.

Kaneka Corporation (Headquarters: Tokyo; President: Kazuhiko Fujii) acquired 96.8% of shares of EndoStream Medical Ltd. (Headquarters Israel; CEO: Danel Mayer), an Israeli medical equipment company, on December 23,2024.

Kaneka Corporation (Headquarters: Tokyo; President: Kazuhiko Fujii) acquired 96.8% of shares of EndoStream Medical Ltd. (Headquarters Israel; CEO: Danel Mayer), an Israeli medical equipment company, on December 23,2024.

Read also – Dr. Doodley Secures Pre-Seed Investment From Campus Fund

By combining Kaneka’s manufacturing and ESM’s technology, we will jointly develop new medical devices, mainly for cerebrovascular treatment, in addition to the Nautilus™ device for aneurysm treatment currently under development. We aim to achieve sales of over 20 billion yen by 2030.

Read also – Endowus Secures $17.5 Mn in latest Funding Round

ESM is a manufacturer of innovative technologies in the field of cerebrovascular diseases and is developing a device for the treatment of cerebral aneurysms called “Nautilus™” that can treat aneurysms with wide openings in cerebral blood vessels, which has been awaited by neurovascular community for many years. The device has a special structure that can be used in combination with an aneurysm embolization coil to block blood flow to the aneurysm, facilitating treatment that would otherwise be difficult with existing devices.
The product received regulatory approval in Europe in November 2024, with plans for approval and launch in the United States in the spring of 2026 and in Japan one year later.

Kaneka is developing its business in a wide range of fields, which include devices for the treatment of cardiac, peripheral vascular, and cerebrovascular diseases, as well as medical devices used in the treatment of gastrointestinal tract diseases. In the growing field of cerebrovascular diseases, among others, we provide “i-ED COIL™1”, an embolization coil that prevents damage to cerebral aneurysms that cause subarachnoid hemorrhage, and “Tigertriever™2”, a device for percutaneous transluminal cerebral thrombus retrieval in stroke. Thus, we are expanding our product portfolio for further growth. The Health Care Solution Unit, which includes these medical businesses, aims to achieve sales of 300 billion yen by 2030.

About Kaneka

Kaneka offers solutions, for people, society, and the global environment in four business domains (Solution Unit “SU”). Solutions Vehicles (SVs), located under the four SUs, serve as engines of change and growth, by bridging the gap between Kaneka and society.

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular